Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials
| dc.contributor.author | Aygoren-Pursun, Emel | |
| dc.contributor.author | Cohn, Danny M. | |
| dc.contributor.author | Agmon-Levin, Nancy | |
| dc.contributor.author | Banerji, Aleena | |
| dc.contributor.author | Bernstein, Jonathan A. | |
| dc.contributor.author | Busse, Paula | |
| dc.contributor.author | Cancian, Mauro | |
| dc.contributor.author | De Castro, Eunice Dias | |
| dc.contributor.author | Farkas, Henriette | |
| dc.contributor.author | Grivcheva-Panovska, Vesna | |
| dc.contributor.author | Hagin, David | |
| dc.contributor.author | Hakl, Roman | |
| dc.contributor.author | Honda, Daisuke | |
| dc.contributor.author | Kessel, Aharon | |
| dc.contributor.author | Kinaciyan, Tamar | |
| dc.contributor.author | Kurowski, Marcin | |
| dc.contributor.author | Li, H. Henry | |
| dc.contributor.author | Lleonart Bellfill, Ramon | |
| dc.contributor.author | Longhurst, Hilary J. | |
| dc.contributor.author | Lumry, William R. | |
| dc.contributor.author | Magerl, Markus | |
| dc.contributor.author | Martinez-Saguer, Inmaculada | |
| dc.contributor.author | Melamed, Isaac | |
| dc.contributor.author | Psarros, Fotis | |
| dc.contributor.author | Savic, Sinisa | |
| dc.contributor.author | Soteres, Daniel F. | |
| dc.contributor.author | Staevska, Maria | |
| dc.contributor.author | Stobiecki, Marcin | |
| dc.contributor.author | Wedner, H. James | |
| dc.contributor.author | Zanichelli, Andrea | |
| dc.contributor.author | Hao, James | |
| dc.contributor.author | Patil, Ketan | |
| dc.contributor.author | Iverson, Matthew | |
| dc.contributor.author | Owiredu-Yeboa, Samuel | |
| dc.contributor.author | Smith, Michael D. | |
| dc.contributor.author | Yea, Christopher M. | |
| dc.contributor.author | Audhya, Paul K. | |
| dc.contributor.author | Riedl, Marc A. | |
| dc.contributor.author | Kiani-Alikhan, Sorena | |
| dc.contributor.author | Maurer, Marcus | |
| dc.date.accessioned | 2026-10-19T12:03:57Z | |
| dc.date.available | 2026-10-19T12:03:57Z | |
| dc.date.issued | 2026-07-01 | |
| dc.date.updated | 2026-10-19T11:37:32Z | |
| dc.description.abstract | Background: Clinical trial designs evaluating on-demand therapies for hereditary angioedema attacks have evolved in response to changes in treatment guidelines. Sebetralstat, an oral plasma kallikrein inhibitor, was evaluated in 2 randomized, placebo-controlled clinical trials, which instructed early treatment of attacks with no minimum severity requirement. Objective: Characterize the efficacy and safety of sebetralstat by pooling data from phase 2 and 3 trials. Methods: This pooled analysis included participants (phase 2, aged >= 18 years; phase 3, aged >= 12 years) who received >= 1 dose of study drug (phase 2, sebetralstat 600 mg or placebo; phase 3, sebetralstat 300 mg or 600 mg, or placebo). Efficacy outcomes included times to beginning of symptom relief within 12 h, reduction in severity within 12 h, and complete attack resolution within 24 h. P values were not adjusted for multiplicity. Results: 377 attacks were treated: 87 with sebetralstat 300 mg; 151 with sebetralstat 600 mg; 139 with placebo. Median (interquartile range) time to treatment was 32.5 min (8.0-94.0). Baseline severity was rated as "Mild" (46.2%), "Moderate" (40.6%), or "Severe"/"Very Severe" (12.7%). Compared with placebo, time to beginning of symptom relief was faster with sebetralstat (300 mg; 600 mg [P = 0.0001; P < 0.0001]), as was reduction in severity (P = 0.0038; P < 0.0001) and complete attack resolution (P = 0.0021; P < 0.0001). Median time to beginning of symptom relief was 1.6 h (0.8-7.0) and 1.8 h (1.0-4.3) with sebetralstat 300 mg and 600 mg, respectively, and 8.3 h (1.5 to >12) with placebo. Sebetralstat had a safety profile comparable to placebo. Conclusion: Across phase 2 and 3 clinical trials, sebetralstat enabled early treatment, provided effective symptom relief versus placebo, and was well tolerated, regardless of attack location or baseline severity. | |
| dc.format.extent | 101401 | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.issn | 1939-4551 | |
| dc.identifier.uri | https://hdl.handle.net/2445/232133 | |
| dc.language.iso | eng | |
| dc.publisher | Elsevier Inc. | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.waojou.2026.101401 | |
| dc.relation.isformatof | Versió postprint del document: https://doi.org/10.1016/j.waojou.2026.101401 | |
| dc.relation.ispartof | Aygören Pürsün,E;Cohn,DM;Agmon Levin,N;Banerji,A;Bernstein,JA;Busse,P;Cancian,M et al, Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials, World Allergy Organ. J., 2026;19(7):doi:10.1016/j.waojou.2026.101401, | |
| dc.relation.uri | https://doi.org/10.1016/j.waojou.2026.101401 | |
| dc.rights | (c)ELSEVIER | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.title | Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 1 de 1
Carregant...
- Nom:
- Sebetralstat fon on demand treatment_L.pdf
- Mida:
- 4.38 MB
- Format:
- Adobe Portable Document Format